title: Evaluation of an In Silico PBPK Post-Bariatric Surgery Model through Simulating Oral Drug Bioavailability of Atorvastatin and Cyclosporine.
abstract: An increasing prevalence of morbid obesity has led to dramatic increases in the number of bariatric surgeries performed. Altered gastrointestinal physiology following surgery can be associated with modified oral drug bioavailability (Foral). In the absence of clinical data, an indication of changes to Foral via systems pharmacology models would be of value in adjusting dose levels after surgery. A previously developed virtual "post-bariatric surgery" population was evaluated through mimicking clinical investigations on cyclosporine and atorvastatin after bariatric surgery. Cyclosporine simulations displayed a reduced fraction absorbed through gut wall (fa) and Foral after surgery, consistent with reported observations. Simulated atorvastatin Foral postsurgery was broadly reflective of observed data with indications of counteracting interplay between reduced fa and an increased fraction escaping gut wall metabolism (FG). Inability to fully recover observed atorvastatin exposure after biliopancreatic diversion with duodenal switch highlights the current gap regarding the knowledge of associated biological changes.CPT: Pharmacometrics & Systems Pharmacology (2013) 2, e47; doi:10.1038/psp.2013.23; advance online publication 12 June 2013.
authors.affiliation: Centre for Applied Pharmacokinetic Research, School of Pharmacy and Pharmaceutical Sciences, University of Manchester, Manchester, UK.
authors.forename: A S
authors.initials: AS
authors.lastname: Darwich
authors.forename: D
authors.initials: D
authors.lastname: Pade
authors.forename: K
authors.initials: K
authors.lastname: Rowland-Yeo
authors.forename: M
authors.initials: M
authors.lastname: Jamei
authors.forename: A
authors.initials: A
authors.lastname: Asberg
authors.forename: H
authors.initials: H
authors.lastname: Christensen
authors.forename: D M
authors.initials: DM
authors.lastname: Ashcroft
authors.forename: A
authors.initials: A
authors.lastname: Rostami-Hodjegan
references.citation: JAMA. 2010 Jan 20;303(3):235-41
references.pmid: 20071471
references.citation: J Pharmacokinet Biopharm. 1991 Feb;19(1):21-50
references.pmid: 2023108
references.citation: Br J Clin Pharmacol. 2012 Nov;74(5):774-87
references.pmid: 22463107
references.citation: Health Technol Assess. 2009 Sep;13(41):1-190, 215-357, iii-iv
references.pmid: 19726018
references.citation: Drug Metab Dispos. 2010 Sep;38(9):1499-504
references.pmid: 20519340
references.citation: Obes Surg. 2011 May;21(5):609-15
references.pmid: 20862615
references.citation: Ann Surg. 1993 Jul;218(1):91-6
references.pmid: 8328834
references.citation: Transplant Proc. 1988 Jun;20(3 Suppl 3):351-5
references.pmid: 3291266
references.citation: J Am Soc Nephrol. 2006 Dec;17(12 Suppl 3):S213-7
references.pmid: 17130264
references.citation: Br J Surg. 1982 Nov;69(11):655-7
references.pmid: 7127049
references.citation: Ann Pharmacother. 2005 Apr;39(4):637-42
references.pmid: 15741419
references.citation: Clin Chem. 1999 Mar;45(3):371-81
references.pmid: 10053038
references.citation: Drug Metab Dispos. 2002 Nov;30(11):1280-7
references.pmid: 12386136
references.citation: Drug Metab Dispos. 2007 Aug;35(8):1315-24
references.pmid: 17470524
references.citation: Clin Pharmacol Ther. 2010 Jun;87(6):699-705
references.pmid: 20445535
references.citation: Clin Pharmacol Ther. 2007 Feb;81(2):194-204
references.pmid: 17192770
references.citation: Clin Transplant. 1996 Oct;10(5):414-9
references.pmid: 8930454
references.citation: Curr Drug Metab. 2010 Nov;11(9):716-29
references.pmid: 21189140
references.citation: Br J Pharmacol. 2003 Apr;138(8):1465-74
references.pmid: 12721102
references.citation: J Am Soc Nephrol. 2003 Jun;14(6):1480-6
references.pmid: 12761248
references.citation: Clin Pharmacokinet. 2011 Dec 1;50(12):809-22
references.pmid: 22087867
references.citation: J Pharm Pharmacol. 2012 Jul;64(7):1008-24
references.pmid: 22686346
references.citation: Clin Pharmacol Ther. 1997 Sep;62(3):248-60
references.pmid: 9333100
references.citation: Drug Metab Dispos. 2000 Nov;28(11):1369-78
references.pmid: 11038166
references.citation: Eur J Pharm Sci. 2000 Nov;12(1):51-62
references.pmid: 11121733
references.citation: Clin Pharmacokinet. 2003;42(13):1141-60
references.pmid: 14531725
references.citation: Obes Surg. 2000 Jun;10(3):233-9
references.pmid: 10929154
references.citation: Obes Surg. 1995 Nov;5(4):424-426
references.pmid: 10733839
references.citation: Surg Endosc. 2011 Jul;25(7):2302-7
references.pmid: 21298531
references.citation: Clin Nutr. 2006 Jun;25(3):400-8
references.pmid: 16709438
references.citation: Am J Surg. 1986 Jan;151(1):117-25
references.pmid: 3946743
references.citation: Xenobiotica. 2006 Jun;36(6):473-97
references.pmid: 16769646
references.citation: Expert Opin Drug Metab Toxicol. 2009 Feb;5(2):211-23
references.pmid: 19199378
references.citation: Br J Clin Pharmacol. 1988 May;25(5):579-84
references.pmid: 3044424
references.citation: Diabetes Metab Syndr. 2011 Apr-Jun;5(2):66-70
references.pmid: 22813405
references.citation: AAPS J. 2009 Jun;11(2):225-37
references.pmid: 19381840
references.citation: Dig Dis Sci. 1994 Feb;39(2):315-20
references.pmid: 8313814
references.citation: Surgery. 2005 Aug;138(2):283-90
references.pmid: 16153438
references.citation: Gut. 1987 Feb;28(2):166-70
references.pmid: 3557189
references.citation: Obes Surg. 2008 Nov;18(11):1424-9
references.pmid: 18542849
references.citation: Surgery. 2010 Feb;147(2):282-7
references.pmid: 20004430
references.citation: Ther Drug Monit. 2003 Dec;25(6):665-70
references.pmid: 14639052
references.citation: Clin Pharmacol Ther. 2009 Sep;86(3):311-8
references.pmid: 19494810
references.citation: Pharm Res. 1994 Feb;11(2):301-4
references.pmid: 8165192
references.citation: Obes Surg. 2009 Dec;19(12):1605-11
references.pmid: 19885707
references.citation: Regul Pept. 1989 Feb;24(2):195-208
references.pmid: 2922495
references.citation: Transplant Proc. 1985 Feb;17(1):286-289
references.pmid: 21151751